STERIS plc Consolidated Condensed Statements of Operations (In thousands, except per share data)

Personant	(In thousands, except per share data)		Three Mo Septen						hs Ended ber 30,	
Second										
Cord revenues - restructuring 45,095 417,20 300,450 18,128 Total cost of revenues, net 426,095 418,173 300,450 516,609 501,300 Gross profit 330,037 318,667 516,609 501,500 501,500 Corperating expenses 172,707 175,999 32,377 31,801 Research and development 161,61 162,00 22,378 31,801 Restructuring expenses 76 0,274 19,00 18,100 Restructuring expenses, end 74,77 9,40 14,60 20,100 Incomer from operations 114,26 126,73 25,24 230,80 Net income attributable to none controlling interes 196,00 95,14 91,913 190,100 Sess Net income attributable to none controlling interes 150,00 90,30 91,91 91,91 190,100 Sess Net income attributable to none controlling interes 150,00 90,30 91,91 91,91 91,91 91,91 91,91 91,91 92,91 92,91 92,91 9		(U	naudited)	(U		(Uı	naudite	d)		
Interest of revenues, net from the fire of	Revenues	\$	756,132	\$	736,840	\$	1,425,00	54	\$ 1,433,643	
Total cost of revenues net	Cost of revenues		426,095		417,263		809,45	59	807,305	
Grose profif operating expenses: 330,037 318,667 615,695 624,510 Operating expenses: 172,707 175,999 327,877 354,740 Research and devolopment 16,143 16,249 32,374 318,383 Restructuring expenses 16,143 16,249 32,374 318,383 Income from operations 188,774 19,193 303,31 387,895 Income from operations 141,626 126,73 352,164 20,108 Non-operating expenses, net 7,477 9,426 14,645 20,108 Non-operating expenses, net 7,477 9,426 14,645 20,108 Net income attributable to noncontrolling interests 150 373 8,4 150,609 Net income attributable to shoreholders 80,85,83 9,10 9,10 19,10 Basic \$1,24 \$1,12 \$2,28 \$2,12 Basic \$1,24 \$1,12 \$2,28 \$2,12 Political \$2,35 \$1,10 \$3,50 \$3,60 B	Total cost of revenues - restructuring		_		910		-	_	1,828	
Spelling general, and administrative 172,707 175,959 32,787 35,140 Research and development 16,43 16,249 32,374 31,834 Restricturing expenses 1676 1274 30,31 31,834 Restricturing expenses 18,787 19,249 32,621 336,825 Income from operations 111,63 126,733 255,24 230,821 Non-operating expenses, net 7,477 9,45 14,68 20,104 Income tax repairs 27,78 22,16 14,52 3,799 Net income 18,06 8,142 19,132 19,199 Less: Net income attributable to noncontrolling interest 18,060 8,142 19,132 19,199 Less: Net income attributable to shareholders 2,128 1,12 1,12 19,132 19,199 Basic 5,124 8,12 1,12 2,12 2,12 Carbidated Cordenses bares outstanding 85,17 84,79 85,06 85,16 Basic Assertification 85,10 85,0			426,095		418,173		809,45	59	809,133	
Speciming expension of Salitation (Salitation of Salitation (Salitation of Salitation of S			330,037		318,667		615,60)5	624,510	
Selling general, and administrative 172,70° 175,95° 327,87° 334,49 Research and development 16,13 16,29 32,3° 1,115 Total operating expenses 76 (274) 90 1,115 Income from operations 188,77 91,93 26,03 25,24 23,082 Non-operating expenses, net 7,477 94,06 14,68 20,104 10,000	Operating expenses:									
Restructuring expenses 76 C174 91734 360,341 387,898 Total operating expenses, not 141,263 19,363 360,341 387,689 Non-operating expenses, net 74,777 9,426 14,680 20,108 Note income at rejustable to nanocontrolling interests 150 373 14 50,799 Ket income attributable to nanocontrolling interests 150 373 184 50,600 Ket income attributable to shareholders 150 370 194,08 199,309 Residence attributable to shareholders 8 1,24 \$ 1,00 310,30 \$ 2,20 \$ 2,00 Retinence attributable to shareholders 8 1,24 \$ 1,00 30,30 \$ 2,0 \$ 2,0 Basis controlled to shareholders \$ 1,23 \$ 1,00 \$ 2,0 \$ 2,0 Cash dividends declared per share outstanding used in EPS \$ 2,00 \$ 2,0 \$ 2,0 STEXIB Ste \$ 2,00 \$ 2,0 \$ 2,0 \$ 2,0 Consolidated Condensed Balance Sheets \$ 2,00 \$ 2,0 \$ 2,0 \$ 2,0			172,707		175,959		327,87	77	354,740	
Incent operating expenses 188.774 191,934 360,341 387,898 Incent from operating operating spenses, ret 141,263 120,733 255,264 230,814 Non-operating expenses, ret 17,477 9,426 141,685 20,104 Net income 27,778 22,165 164,525 36,798 Net income attributable to noncontrolling interests 180,008 9,51,22 194,125 197,919 Net income attributable to shareholders 180,508 9,476 194,182 197,939 Net income attributable to shareholders 81,688 9,476 194,182 197,939 Net income attributable to shareholders 81,688 9,476 194,182 197,939 Basic 6 1,48 1,48 1,50 2,12 19,193 Carbilloted Nordinary State (EPS) data 81,12 81,12 82,12 9,07 9,07 Cash and scleared per share outstanding used in EPS computations 85,14 84,79 85,06 84,71 Diluted number of shares outstanding 85,14 84,79 85,76	Research and development		16,143		16,249		32,37	74	31,834	
Inceme from operations 188,774 191,944 300,341 387,089 Inceme from operations 141,263 126,733 255,264 236,821 Non-operating expenses, et 27,778 9,425 14,645 36,798 Net income 27,778 22,165 46,452 36,798 Net income attributable to noncontrolling interests 180 95,142 194,132 179,998 Net income attributable to shareholders 180 9,169 91,413 179,998 Net income attributable to shareholders 180 9,179 9,170 180 Residence of shareholders 180 9,179 9,170 19,179 9,170 Basic 5 1,24 8,121 9,228 9,202 2,00 Cabilided average number of shares outstanding 85,170 8,505 85,761 8,510 Basic 85,170 85,790 85,605 85,760 85,605 Diluted number of shares outstanding 85,84 85,95 85,760 85,605 STERIS ple <td row<="" td=""><td>Restructuring expenses</td><td></td><td>(76)</td><td></td><td>(274)</td><td></td><td>9</td><td>90</td><td>1,115</td></td>	<td>Restructuring expenses</td> <td></td> <td>(76)</td> <td></td> <td>(274)</td> <td></td> <td>9</td> <td>90</td> <td>1,115</td>	Restructuring expenses		(76)		(274)		9	90	1,115
Non-perating expenses, net income tax expense 7,477 9,40 14,680 36,788 36,788 36,789			188,774		191,934		360,34	1 1	387,689	
Non-perating expenses, net income tax expense 7,477 9,40 14,680 36,788 36,788 36,789	T		141.002		107.722		255.24		226.021	
Income Net income 27,78 2,165 46,452 36,798 Net income \$106,008 \$ 9,162 \$1,312 \$1,799 Net income attributable to noncontrolling interess 150 373 84 500 Net income attributable to shareholders \$150 373 84 500 Earnings per ordinary share (EPS) date: \$1,22 \$1,12 \$2,28 \$2,20 Basic \$1,23 \$1,11 \$2,28 \$2,00 Cash dividends declared per share ordinary outstanding \$0,40 \$0,37 \$0,77 \$0,70 Weighted average number of shares outstanding used in EPS computation: \$5,50 \$5,60 <	_									
Net income attributable to noncontrolling interests \$ 106,008 95,142 \$ 13,13 \$ 1,50 Less: Net income attributable to shareholders \$ 15,50 3733 \$ 4 5,60 Net income attributable to shareholders \$ 10,508\$ \$ 94,609 \$ 11,00 \$ 170,305 Earnings per ordinary share (EPS) data: \$ 1,24 \$ 1,12 \$ 2,28 \$ 2,12 Basic \$ 1,23 \$ 1,11 \$ 2,28 \$ 2,09 Cash dividends declared per share ordinary outstanding \$ 0,00 \$ 0,37 \$ 0,77 \$ 0,77 Weighted average number of shares outstanding used in EPS computation: \$ 85,170 \$ 84,795 \$ 85,605 \$ 84,716 Basic number of shares outstanding \$ 85,84 \$ 8,695 \$ 85,605 \$ 84,716 Diluted number of shares outstanding \$ 85,84 \$ 8,695 \$ 85,605 \$ 84,716 Diluted number of shares outstanding \$ 85,81 \$ 86,985 \$ 85,605 \$ 84,716 Diluted number of shares outstanding \$ 85,81 \$ 85,605 \$ 85,605 \$ 84,716 Consolidated Condensed Balance Sheets \$ 1,200					-		-			
Less: Net income attributable to sharcholders 150 373 84 500 Net income attributable to sharcholders 100,828 9,107,00 119,100 <th< td=""><td>-</td><td>Φ.</td><td></td><td>Ф</td><td></td><td></td><td></td><td></td><td></td></th<>	-	Φ.		Ф						
Section		\$		\$		\$	-			
Earnings per ordinary share (EPS) data: Basic \$ 1.24 \$ 1.12 \$ 2.28 \$ 2.19 Diluted \$ 1.23 \$ 1.11 \$ 2.26 \$ 2.09 Cash dividends declared per share ordinary outstanding \$ 0.40 \$ 0.37 \$ 0.77 \$ 0.71 Weighted average number of shares outstanding used in EPS computation: Basic number of shares outstanding 85,170 84,795 85,065 84,716 Diluted number of shares outstanding 85,844 85,695 85,760 85,005 STERIN ple Consolidated Condensed Balance Sheets (in thousands) (Unautter) Earning to the consolidated Condensed Balance Sheets (in thousands) (September 30, 2020 March 31, 2020 Consolidated Condensed Balance Sheets (in thousands) (Unautter) (Unautter) (Unautter) (Unautter) (Unautter) (Unautter) (Unautter) (Unautter) (Unautter) (Unautter) <td colsp<="" td=""><td></td><td>Φ.</td><td></td><td>Φ.</td><td></td><td></td><td></td><td></td><td></td></td>	<td></td> <td>Φ.</td> <td></td> <td>Φ.</td> <td></td> <td></td> <td></td> <td></td> <td></td>		Φ.		Φ.					
Basic S 1.24 S 1.12 S 2.28 S 2.12 Diluted S 2.28 S 2.09 S 2.28 S	Net income attributable to shareholders	\$	105,858	\$	94,769	\$	194,04	18	\$ 179,359	
Basic S 1.24 S 1.12 S 2.28 S 2.12 Diluted S 2.28 S 2.09 S 2.28 S	Farnings now audinous share (FDS) data.									
Diluted S 1.23 S 1.10 \$ 2.26 \$ 2.09 Cash dividends declared per share ordinary outstanding \$ 0.40 \$ 0.37 \$ 0.77 \$ 0.71 Weighted average number of shares outstanding used in EPS computation: Basic number of shares outstanding 85,170 84,795 85,065 85,700 Diluted number of shares outstanding 85,844 85,695 85,700 85,600 STERIS plc Consolidated Condensed Balance Sheets (tunautiet) Experimental Sheets Current assets Cash and cash equivalents September 30, March 31, 2028 March 31, 2020 (unautiet) March 31, 2020 (unautiet) (unautiet) Span="4">(unautiet) Span="4">(unautiet) March 31, 2020 (unautiet) (unautiet) March 31, 2020 (unautiet) (unautiet) (unautiet) (unautiet) (unautiet) (unautiet) (unautiet) (unautiet)		ø.	1 24	d ^a	1 12	ø	2.0	10	¢ 2.12	
Cash dividends declared per share ordinary outstanding used in EPS computation: Basic number of shares outstanding 85,17 84,79 85,065 84,716 1011uted number of shares outstanding 85,844 85,695 85,760 85,630		3			1.12					
Weighted average number of shares outstanding used in EPS computation: Basic number of shares outstanding 85,170 84,795 85,055 84,716 Diluted number of shares outstanding 85,844 85,695 85,760 85,630 STERIS ple Consolidated Condensed Balance Sheets (in thousands) September 30, 2020 March 31, 2020 Curent assets Cash and cash equivalents \$ 312,028 \$ 319,581 Acounts receivable, net \$ 503,724 \$ 58,648 Acounts receivable, net \$ 503,724 \$ 58,648 Acounts receivable, net \$ 503,724 \$ 58,648 Inventories, net \$ 53,025 \$ 54,455 Prepaid expenses and other current assets \$ 1,176,066 \$ 1,118,85 Acounts necesses, net \$ 143,041 \$ 13,837 Class right-of-use assets, net \$ 143,041 \$ 13,837 Other assets \$ 5,492,507 \$ 5,692,83 Total assets \$ 5,492,507	Diluted	3	1.23	Þ	1.11	3	2.2	20		
computation: 85,170 84,795 85,065 84,710 85,065 85,065 85,063	Cash dividends declared per share ordinary outstanding	\$	0.40	\$	0.37	\$	0.7	77	\$ 0.71	
Diluted number of shares outstanding 85,844 85,695 85,760 85,630 STERIS plc Consolidated Condensed Balance Sheets (in thousands) September 30, 2020 March 31, 2020 Current assets Current assets Cash and cash equivalents \$ 312,028 \$ 319,581 Accounts receivable, net 503,724 \$ 586,481 Inventories, net 278,593 248,259 Prepaid expenses and other current assets 55,965 54,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,857 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 55,022 565,473 Other assets 55,022 565,473 Other assets 55,022 565,473 Total current liabilities 310,474 354,266 Current liabilities 310,474 354,266 Total current liabilities 310,474 354,266 Total current liabilities 310,474 354,266 Total current liabilities 314,04										
STERIS plc Consolidated Condensed Balance Sheets (in thousands) September 30, 2020 March 31, 2020 to unaudited Tourent assets Current assets Cash and cash equivalents \$ 312,028 \$ 319,581 Accounts receivable, net \$ 53,724 \$ 586,481 Inventories, net \$ 278,593 248,259 Prepaid expenses and other current assets \$ 1,760,66 1,118,851 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,118,851 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intagibles, net 55,102 55,172 51,818 Other assets 55,192 5,183 Total assets 55,192 5,183 Total assets 5,492,567 5,425,582 Total assets 5,492,567 5,425,582 Counts payable 8 14,944 34,184 Other current liabilities 310,474	Basic number of shares outstanding		85,170		84,795		85,06	55	84,716	
Consolidated Condensed Balance Sheets (in thousands) September 30, 2020 March 31, 2020 (Unaudited) Corrent assets Cash and cash equivalents \$ 312,028 \$ 319,581 Accounts receivable, net 503,724 586,481 Inventories, net 278,593 248,259 Prepaid expenses and other current assets 1,150,301 1,208,751 Total current assets 1,150,301 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intagibles, net 55,022 565,473 Other assets 55,122 51,818 Total assets 55,122 51,828 Other assets 55,122 51,829 Total sasets 55,122 51,829 Other current liabilities 51,242,545 51,242,545 Accounts payable 5 124,944 \$ 149,341 314,474 354,266 Total current liabilities 310,474 </td <td>Diluted number of shares outstanding</td> <td></td> <td>85,844</td> <td></td> <td>85,695</td> <td></td> <td>85,76</td> <td>50</td> <td>85,630</td>	Diluted number of shares outstanding		85,844		85,695		85,76	50	85,630	
Current assets: Salaya S	Consolidated Condensed Balance Sheets				_		30,			
Assets Cash and cash equivalents \$ 312,028 \$ 319,581 Accounts receivable, net 503,724 586,481 Inventories, net 278,593 248,259 Prepaid expenses and other current assets 55,965 54,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets 55,492,567 5,425,582 Current liabilities: \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 310,474 354,266 Total current liabilities 335,418 503,607 Ling-term indebtedness 374,140 364,730 Total equity 362,455 3,406,724							d)			
Current assets: Cash and cash equivalents \$ 312,028 \$ 319,581 Accounts receivable, net 503,724 \$ 586,481 Inventories, net 278,593 248,259 Prepaid expenses and other current assets 55,965 5,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 5,425,582 Total assets 5,492,567 5,425,582 Example of the current liabilities 310,474 354,266 Current liabilities 310,474 354,266 Total current liabilities 335,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total current liabilities 374,140 364,730	Assets				(0		,			
Cash and cash equivalents \$ 312,028 \$ 319,581 Accounts receivable, net 503,724 586,481 Inventories, net 278,593 248,259 Prepaid expenses and other current assets 55,965 54,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets \$ 5,492,567 \$ 5,425,582 Eurrent liabilities \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724										
Accounts receivable, net 503,724 586,481 Inventories, net 278,593 248,259 Prepaid expenses and other current assets 55,965 54,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets 5,492,567 5,425,582 Current liabilities 310,474 354,266 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Cash and cash equivalents				\$	312	2,028	\$	319,581	
Prepaid expenses and other current assets 55,965 54,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets 55,492,567 5,425,582 Current liabilities 4 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,406,745 3,406,744						503	,724			
Prepaid expenses and other current assets 55,965 54,430 Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets 55,492,567 5,425,582 Total assets 8 5,492,567 5,425,582 Current liabilities 8 124,944 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Inventories, net					278	3,593		248,259	
Total current assets 1,150,310 1,208,751 Property, plant, and equipment, net 1,176,066 1,111,855 Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets \$5,492,567 \$5,425,582 Current liabilities \$124,944 \$149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Prepaid expenses and other current assets					55	,965		54,430	
Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets Liabilities and equity Current liabilities: Accounts payable \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724						1,150	,310		1,208,751	
Lease right-of-use assets, net 143,041 131,837 Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets Liabilities and equity Current liabilities: Accounts payable \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724										
Goodwill 2,417,956 2,356,085 Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets \$5,492,567 \$5,425,582 Current liabilities: Accounts payable Other current liabilities \$124,944 \$149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Property, plant, and equipment, net					1,176	,066		1,111,855	
Intangibles, net 550,022 565,473 Other assets 55,172 51,581 Total assets \$ 5,492,567 \$ 5,425,582 Current liabilities: Accounts payable Other current liabilities \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Lease right-of-use assets, net					143	,041		131,837	
Other assets 55,172 51,581 Total assets 5,492,567 \$5,425,582 Liabilities and equity Current liabilities: Accounts payable \$124,944 \$149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Goodwill					2,417	,956		2,356,085	
Total assets \$ 5,492,567 \$ 5,425,582 Liabilities and equity Current liabilities: Accounts payable \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Intangibles, net									
Liabilities and equity Current liabilities:	Other assets						-			
Current liabilities: Accounts payable \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	Total assets				\$	5,492	2,567	\$	5,425,582	
Accounts payable \$ 124,944 \$ 149,341 Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724										
Other current liabilities 310,474 354,266 Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724										
Total current liabilities 435,418 503,607 Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724	* *				\$		*	\$		
Long-term indebtedness 1,020,554 1,150,521 Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724										
Other liabilities 374,140 364,730 Total equity 3,662,455 3,406,724							-			
Total equity 3,662,455 3,406,724						1.020).554		1,150,521	
	0.4 11.1.11.11									
Total liabilities and equity \$ 5,492,567 \$ 5,425,582						374	,140		364,730	
	Total equity					374 3,662	1,140 2,455		364,730 3,406,724	

STERIS plc

Segment Data

Financial information for each of the segments is presented in the following table. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. Segment income is calculated as the segment's gross profit less direct costs and indirect costs if the resources are dedicated to a single segment. Corporate costs include corporate and administrative functions, public company costs, legacy post-retirement benefits, and certain services and facilities related to distribution and research and development that are shared by multiple segments.

		Three Mon Septem				Six Mont Septem		
		2020		2019		2020		2019
	(u	naudited)	(u	naudited)	(1	unaudited)	(1	unaudited)
Revenues:								
Healthcare	\$	470,927	\$	485,283	\$	870,585	\$	931,015
Applied Sterilization Technologies		169,547		152,907		321,909		307,193
Life Sciences		115,658		98,650		232,570		195,435
Total revenues	\$	756,132	\$	736,840	\$	1,425,064	\$	1,433,643
Operating income (loss):								
Healthcare	\$	104,796	\$	103,035	\$	187,153	\$	193,550
Applied Sterilization Technologies		76,835		65,386		140,790		133,421
Life Sciences		46,433		32,315		94,894		65,354
Corporate		(58,155)		(50,956)		(110,522)		(106,353)
Total operating income before adjustments	\$	169,909	\$	149,780	\$	312,315	\$	285,972
Less: Adjustments								
Amortization of acquired intangible assets	\$	21,955	\$	18,952	\$	39,455	\$	35,901
Acquisition and integration related charges		1,135		1,947		2,421		3,864
Redomiciliation and tax restructuring costs		384		1,016		554		2,786
Net (gain) loss on divestiture of businesses		(5)		50		5		2,476
Amortization of property "step up" to fair value		714		446		1,317		1,181
COVID-19 incremental costs		4,539		_		13,209		_
Restructuring charges		(76)		636		90		2,943
Total operating income	\$	141,263	\$	126,733	\$	255,264	\$	236,821

STERIS plc Consolidated Condensed Statements of Cash Flows (in thousands)

(iii tiiousailus)	Six	x Months Ende	d Se	ptember 30,
		2020		2019
Operating activities:	((Unaudited)	(Unaudited)
Net income	\$	194,132	\$	179,919
Non-cash items		124,017		112,706
Changes in operating assets and liabilities		(22,076)		(32,625)
Net cash provided by operating activities		296,073		260,000
Investing activities:				
Purchases of property, plant, equipment, and intangibles, net		(110,746)		(98,168)
Proceeds from the sale of property, plant, equipment, and intangibles		275		206
Proceeds from the sale of businesses				439
Acquisition of businesses, net of cash acquired		_		(87,935)
Other		(2,392)		_
Net cash used in investing activities		(112,863)		(185,458)
Financing activities:				
Payments on long-term obligations		(35,000)		
Proceeds (payments) under credit facilities, net		(107,162)		13,240
Deferred financing fees and debt issuance costs		_		(1,206)
Acquisition related deferred or contingent consideration		(42)		(452)
Repurchases of ordinary shares		(14,434)		(37,866)
Cash dividends paid to ordinary shareholders		(65,560)		(60,220)
Contributions from noncontrolling interest		2,258		_
Stock option and other equity transactions, net		20,621		22,975
Net cash used in financing activities		(199,319)		(63,529)
Effect of exchange rate changes on cash and cash equivalents		8,556		(6,110)
Increase (decrease) in cash and cash equivalents		(7,553)		4,903
Cash and cash equivalents at beginning of period		319,581		220,633
Cash and cash equivalents at end of period	\$	312,028	\$	225,536

The following table presents a financial measure which is considered to be "non-GAAP financial measures" under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to pay cash dividends, fund growth outside of core operations, fund future debt principal repayments, and repurchase shares. STERIS's calculation of free cash flows may vary from other companies.

	S	ix Months End	ed S	eptember 30,
		2020		2019
		(Unaudited)		(Unaudited)
Calculation of Free Cash Flow:				
Cash flows from operating activities	\$	296,073	\$	260,000
Purchases of property, plant, equipment, and intangibles, net		(110,746)		(98,168)
Proceeds from the sale of property, plant, equipment, and intangibles		275		206
Free Cash Flow	\$	185,602	\$	162,038

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

Management and the Board of Directors believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provides the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

To measure the percentage organic revenue growth, the Company removes the impact of acquisitions and divestitures that affect the comparability and trends in revenue. To measure the percentage constant currency organic revenue growth, the impact of changes in currency exchange rates and acquisitions and divestitures that affect the comparability and trends in revenue are removed. The impact of changes in currency exchange rates is calculated by translating current year results at prior year average currency exchange rates.

	_				7	Three mont	hs ei	ided Septer	nbe	r 30, (unaud	lited)		
		As report	ed,	GAAP		npact of quisitions		npact of vestitures	(C	mpact of Foreign Currency Jovements	GAAP Growth	Organic Growth	Constant Currency Organic Growth
		2020		2019		2020		2019		2020	2020	2020	2020
Segment revenues:													
Healthcare	\$	470,927	\$	485,283	\$	_	\$	_	\$	1,169	(3.0)%	(3.0)%	(3.2)%
Applied Sterilization Technologies		169,547		152,907		_		_		2,624	10.9 %	10.9 %	9.2 %
Life Sciences		115,658		98,650		_		_		1,076	17.2 %	17.2 %	16.2 %
Total	\$	756,132	\$	736,840	\$		\$		\$	4,869	2.6 %	2.6 %	2.0 %
						Six months	end	led Septem	ber	30. (unaudit	ted)		

				1		,		
	As report	ed, GAAP	Impact of Acquisitions	Impact of Divestitures	Impact of Foreign Currency Movements	GAAP Growth	Organic Growth	Constant Currency Organic Growth
	2020	2019	2020	2019	2020	2020	2020	2020
Segment revenues:								
Healthcare	\$ 870,585	\$ 931,015	\$ —	\$	\$ (971)	(6.5)%	(6.5)%	(6.4)%
Applied Sterilization Technologies	321,909	307,193	_	_	1,061	4.8 %	4.8 %	4.4 %
Life Sciences	232,570	195,435	_	_	424	19.0 %	19.0 %	18.8 %
Total	\$ 1,425,064	\$ 1,433,643	\$ —	\$ —	\$ 514	(0.6)%	(0.6)%	(0.6)%

			Three mont	hs ended Sej	otember 30, (unaudited)				
	Gross	Profit	Income Opera	e from ations	Net In attribut sharel			Dilute	ed EP	P S
	2020	2019	2020	2020 2019		2019	2020		2	2019
GAAP	\$ 330,037	\$ 318,667	\$141,263	\$ 126,733	\$ 105,858	\$ 94,769	\$	1.23	\$	1.11
Adjustments:										
Amortization of acquired intangible assets	5,008	759	21,955	18,952						
Acquisition and integration related charges	101	313	1,135	1,947						
Redomiciliation and tax restructuring costs	_	_	384	1,016						
Net (gain) loss on divestiture of businesses	_	_	(5)	50						
Amortization of property "step up" to fair value	707	492	714	446						
COVID-19 incremental costs	4,132	_	4,539	_						
Restructuring charges	_	910	(76)	636						
Consideration received for pre-acquisitition arrangement					(819)					
Net impact of adjustments after tax*					22,305	18,363				
Net EPS impact								0.25		0.21
Adjusted	\$ 339,985	\$ 321,141	\$169,909	\$ 149,780	\$ 127,344	\$ 113,132	\$	1.48	\$	1.32

^{*} The tax expense includes both the current and deferred income tax impact of the adjustments.

			Six months	ended Septe	ember 30, (u	naudited)				
	Gross	Income from Attributable to Gross Profit Operations shareholders								
	2020	2019	2020	2019	2020	2019	2	2020	2	2019
GAAP	\$ 615,605	\$ 624,510	\$255,264	\$ 236,821	\$194,048	\$ 179,359	\$	2.26	\$	2.09
Adjustments:										
Amortization of acquired intangible assets	5,350	906	39,455	35,901						
Acquisition and integration related charges	193	809	2,421	3,864						
Redomiciliation and tax restructuring costs	_	_	554	2,786						
Net loss on divestiture of businesses	_	_	5	2,476						
Amortization of property "step up" to fair value	1,310	1,274	1,317	1,181						
COVID-19 incremental costs	12,468	_	13,209	_						
Restructuring charges	_	1,828	90	2,943						
Consideration received for pre-acquisitition arrangement					(819)					
Net impact of adjustments after tax*					45,935	38,783				
Net EPS impact								0.53		0.46
Adjusted	\$ 634,926	\$ 629,327	\$312,315	\$ 285,972	\$239,164	\$ 218,142	\$	2.79	\$	2.55

^{*} The tax expense includes both the current and deferred income tax impact of the adjustments.

STERIS plc Unaudited Supplemental Financial Data Second Quarter Fiscal 2021

For the Periods Ending September 30, 2020 and 2019

	FY 2021	FY 2020	FY 2021	FY 2020
Total Company Revenues	Q2	Q2	YTD	YTD
Consumables	\$ 178,590	\$ 158,573	\$ 321,186	\$ 318,684
Service	416,628	399,174	784,452	788,242
Total Recurring	\$ 595,218	\$ 557,747	\$ 1,105,638	\$ 1,106,926
Capital Equipment	\$ 160,914	\$ 179,093	\$ 319,426	\$ 326,717
Total Revenues	\$ 756,132	\$ 736,840	\$ 1,425,064	\$ 1,433,643
Ireland Revenues	\$ 17,090	\$ 15,171	\$ 31,463	\$ 30,279
Ireland Revenues as a % of Total	2 %	2 %	2 %	2 %
United States Revenues	\$ 549,449	\$ 538,101	\$ 1,041,157	\$ 1,049,253
United States Revenues as a % of Total	73 %	73 %	73 %	73 %
International Revenues	\$ 189,593	\$ 183,568	\$ 352,444	\$ 354,111
International Revenues as a % of Total	25 %	25 %	25 %	25 %

Segment Data		FY 2021	FY 2020	FY 2021	FY 2020
Healthcare		Q2	Q2	YTD	YTD
Revenues					
Consumables	\$	122,797	\$ 116,033	\$ 206,551	\$ 232,115
Service		216,457	216,619	404,279	425,414
Total Recurring	\$	339,254	\$ 332,652	\$ 610,830	\$ 657,529
Capital Equipment		131,673	152,631	259,755	273,486
Total Healthcare Revenues	\$	470,927	\$ 485,283	\$ 870,585	\$ 931,015
Segment Operating Income	\$	104,796	\$ 103,035	\$ 187,153	\$ 193,550
	Г				
Applied Sterilization Technologies					
Applied Sterilization Technologies Revenues	\$	169,547	\$ 152,907	\$ 321,909	\$ 307,193
Segment Operating Income	\$	76,835	\$ 65,386	\$ 140,790	\$ 133,421
Life Sciences					
Revenues					
Consumables	\$	55,793	\$ 42,540	\$ 114,635	\$ 86,569
Service		30,624	29,648	58,264	55,635
Total Recurring	\$	86,417	\$ 72,188	\$ 172,899	\$ 142,204
Capital Equipment		29,241	26,462	59,671	53,231
Total Life Sciences Revenues	\$	115,658	\$ 98,650	\$ 232,570	\$ 195,435
Segment Operating Income	\$	46,433	\$ 32,315	\$ 94,894	\$ 65,354
Corporate					
Operating loss	\$	(58,155)	\$ (50,956)	\$ (110,522)	\$ (106,353)

Other Data	П	FY 2021	FY 2020	FY 2021	FY 2020
	П	Q2	Q2	YTD	YTD
Healthcare Backlog	\$	178,027	\$ 199,264		
Life Sciences Backlog		74,824	69,728		
Total Backlog	\$	252,851	\$ 268,992		
GAAP Income Tax Rate		20.8 %	18.9 %	19.3 %	17.0 %
Adjusted Income Tax Rate		21.1 %	19.1 %	19.4 %	17.7 %

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company's most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.